Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
36.30 USD   +1.77%
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds
Communiqués de presse de la société ULTRAGENYX PHARMACEUTICAL INC.
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/10Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
11/10Ultragenyx Announces Departure of Chief Financial Officer
GL
11/09Ultragenyx to Present at Upcoming Healthcare Conferences
GL
11/09Ultragenyx to Present at Upcoming Healthcare Conferences
AQ
11/03ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
11/02Ultragenyx : Q3 Earnings Snapshot
AQ
11/02Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
GL
11/02Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
AQ
10/28Ultragenyx Pharmaceutical Inc. : Submission of Matters to a Vote of Security Holders (form..
AQ
10/27Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corpora..
GL
10/05Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
10/04Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/15Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
09/12Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
AQ
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/09Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
GL
09/01Ultragenyx to Participate at Citi BioPharma Conference
GL
09/01Ultragenyx to Participate at Citi BioPharma Conference
AQ
08/18Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
08/17Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
08/17Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/04Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
08/03Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
07/29Ultragenyx Pharmaceutical : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
07/29ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
07/28Ultragenyx Pharmaceutical : Reports Second Quarter 2022 Financial Results and Corporate Up..
PU
07/28Ultragenyx : Q2 Earnings Snapshot
AQ
07/28Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
GL
07/28Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
GL
07/25Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
GL
07/25Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
GL
07/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
07/20Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
07/18Ultragenyx Pharmaceutical : and GeneTx Provide Program Update on GTX-102 for Angelman Synd..
PU
07/18Ultragenyx Pharmaceutical Inc. : Entry into a Material Definitive Agreement, Completion of..
AQ
07/18Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including..
GL
07/15Ultragenyx announces sale of a portion of future north american royalties on crysvita f..
AQ
07/14Ultragenyx Pharmaceutical : Announces Sale of a Portion of Future North American Royalties..
PU
07/14Ultragenyx Pharmaceutical Inc. : Entry into a Material Definitive Agreement, Other Events,..
AQ
07/14Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® ..
GL
07/14Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® ..
GL
06/27Ultragenyx Pharmaceutical Inc. : Submission of Matters to a Vote of Security Holders (form..
AQ
06/10Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
GL
06/10Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
GL
06/01Ultragenyx to Present at Jefferies Global Healthcare Conference
GL
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
GL
05/19Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
AQ
05/17Ultragenyx Pharmaceutical Inc. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
GL
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
AQ
05/09Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
GL
05/09Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
AQ
05/06ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
05/05Ultragenyx : Q1 Earnings Snapshot
AQ
05/05Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
GL
05/05Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
AQ
05/03Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
05/03Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
GL
05/03Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
GL
04/27Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corpora..
GL
04/27Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corpora..
GL
04/25Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
GL
04/25Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
GL
04/22Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
04/22Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
AQ
04/21Mereo's Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical ..
AQ
04/20Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusu..
AQ
03/02Ultragenyx to Participate in the Cowen Health Care Conference
AQ
02/15ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
1  2  3  4  5  6  7Next
Upcoming event on ULTRAGENYX PHARMACEUTICAL INC.